Loncar China BioPharma ETF
CHNA
CHNA was delisted on the 20th of October, 2023.
6 hedge funds and large institutions have $1.86M invested in Loncar China BioPharma ETF in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 2 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
195% more capital invested
Capital invested by funds: $631K → $1.86M (+$1.23M)
50% more funds holding
Funds holding: 4 → 6 (+2)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$1.5M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$38.9K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$41 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FEM
Fulcrum Equity Management
Plano,
Texas
|
-$25.6K |
| 2 |
MCM
MV Capital Management
Bethesda,
Maryland
|
-$19K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$3.75K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $1.37M | +$1.5M | +36,836 | New |
|
|
FEM
2
Fulcrum Equity Management
Plano,
Texas
| $340K | -$25.6K | -629 | -6% |
|
3
Morgan Stanley
New York
| $82K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $36K | +$38.9K | +954 | New |
|
|
5
Osaic Holdings
Scottsdale,
Arizona
| $31K | -$3.75K | -92 | -10% |
|
|
MCM
6
MV Capital Management
Bethesda,
Maryland
| – | -$19K | -400 | Closed |
|
|
7
Fidelity Investments
Boston,
Massachusetts
| – | +$41 | +1 | New |
|
CHNA Hedge Fund Activity: Q3 2021 in Review
6 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q3 2021, worth a combined $1.86M — up 195% from $631K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CHNA positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $1.5M. The largest seller was Fulcrum Equity Management, cutting an estimated $25.6K.
- 6 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q3 2021, up from 4 in Q2 2021.
- Funds reported $1.86M of Loncar China BioPharma ETF stock for Q3 2021, up 195% quarter-over-quarter.
- 3 funds opened new Loncar China BioPharma ETF positions in Q3 2021 and 1 closed out, a net change of +2 holders.
- The largest Loncar China BioPharma ETF buyer in Q3 2021 was Jane Street, an estimated $1.5M added.
- The largest Loncar China BioPharma ETF seller in Q3 2021 was Fulcrum Equity Management, an estimated $25.6K sold.
Based on aggregated 13F filings for Q3 2021.